ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $10,305,618 | +2.6% | 251,602 | +17.0% | 2.63% | -2.0% |
| Q1 2024 | $10,043,112 | +25.2% | 215,102 | +29.2% | 2.68% | +20.1% |
| Q4 2023 | $8,020,594 | +95.2% | 166,506 | +44.5% | 2.23% | +82.8% |
| Q3 2023 | $4,108,341 | -21.5% | 115,241 | +2.7% | 1.22% | +10.7% |
| Q2 2023 | $5,236,042 | +17.9% | 112,241 | +1.4% | 1.10% | -26.0% |
| Q1 2023 | $4,440,714 | -7.9% | 110,741 | +3.7% | 1.49% | -18.4% |
| Q4 2022 | $4,821,491 | +44.4% | 106,741 | +29.6% | 1.83% | +50.7% |
| Q3 2022 | $3,339,000 | -46.6% | 82,341 | -21.5% | 1.21% | -41.5% |
| Q2 2022 | $6,258,000 | -23.6% | 104,899 | -6.9% | 2.07% | +14.6% |
| Q1 2022 | $8,186,000 | -4.6% | 112,727 | +10.7% | 1.81% | +6.4% |
| Q4 2021 | $8,579,000 | – | 101,831 | – | 1.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
| Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
| Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
| AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
| EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
| FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
| HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
| Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |